why choose us

First received: March 27, 2023

Clinical Trial: Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults

Study Status: Completed

Recruit Status: RECRUITING

Condition: Gliomas

Study Type: INTERVENTIONAL


Official Title: Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults

Brief Summary: To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors

Read more